Banque Pictet & Cie SA cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 11.8% during the 1st quarter, Holdings Channel reports. The firm owned 169,954 shares of the biotechnology company’s stock after selling 22,806 shares during the quarter. Banque Pictet & Cie SA’s holdings in Arrowhead Pharmaceuticals were worth […]
By Chris Wack Arrowhead Pharmaceuticals said Monday that it has filed an application in New Zealand to initiate a Phase 1/2 clinical trial of ARO-DUX4, its.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) insider Tracie Oliver sold 8,925 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.31, for a total transaction of $315,141.75. Following the sale, the insider now owns 61,575 shares in the company, valued at $2,174,213.25. […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) insider James C. Hamilton sold 3,000 shares of the stock in a transaction on Friday, June 30th. The shares were sold at an average price of $35.53, for a total transaction of $106,590.00. Following the completion of the sale, the insider now directly owns 188,484 shares in the […]
Endurant Capital Management LP bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,187 shares of the biotechnology company’s stock, valued at approximately $1,143,000. Several other large investors have […]